New drug combo targets genetic weakness in advanced breast cancer
Disease control
Terminated
This study tests a drug called fluzoparib, either alone or with another drug called camrelizumab, in people with a specific type of advanced breast cancer (HRD-positive, HER2-negative). The goal is to see if these treatments can shrink tumors or slow the cancer's growth. About 80…
Phase: PHASE2 • Sponsor: wang shusen • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC